IL163993A0 - Method for treating cognitive disorders - Google Patents
Method for treating cognitive disordersInfo
- Publication number
- IL163993A0 IL163993A0 IL16399303A IL16399303A IL163993A0 IL 163993 A0 IL163993 A0 IL 163993A0 IL 16399303 A IL16399303 A IL 16399303A IL 16399303 A IL16399303 A IL 16399303A IL 163993 A0 IL163993 A0 IL 163993A0
- Authority
- IL
- Israel
- Prior art keywords
- cognitive disorders
- treating cognitive
- treating
- disorders
- cognitive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36706802P | 2002-03-22 | 2002-03-22 | |
US10/386,915 US20040024043A1 (en) | 2002-03-22 | 2003-03-12 | Method for treating cognitive disorders |
PCT/US2003/008407 WO2003082270A1 (fr) | 2002-03-22 | 2003-03-18 | Procede destine au traitement de troubles cognitifs |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163993A0 true IL163993A0 (en) | 2005-12-18 |
Family
ID=28678179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16399303A IL163993A0 (en) | 2002-03-22 | 2003-03-18 | Method for treating cognitive disorders |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040024043A1 (fr) |
EP (1) | EP1490057A4 (fr) |
JP (1) | JP2005526806A (fr) |
KR (1) | KR100609381B1 (fr) |
CN (1) | CN1642541A (fr) |
AU (1) | AU2003230683B2 (fr) |
BR (1) | BR0306855A (fr) |
CA (1) | CA2476923A1 (fr) |
HR (1) | HRP20040992A2 (fr) |
IL (1) | IL163993A0 (fr) |
MX (1) | MXPA04009136A (fr) |
NO (1) | NO20044530L (fr) |
NZ (1) | NZ534726A (fr) |
PL (1) | PL372315A1 (fr) |
RU (1) | RU2280449C2 (fr) |
WO (1) | WO2003082270A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007512338A (ja) * | 2003-11-21 | 2007-05-17 | メモリー・ファーマシューティカルズ・コーポレイション | L型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法 |
EP1737445A4 (fr) | 2004-03-19 | 2007-05-09 | Axonyx Inc | Methode permettant de traiter le syndrome de down |
EP1740172A4 (fr) * | 2004-03-19 | 2007-10-10 | Axonyx Inc | Inhibiteurs d'acetylcholinesterase et antagonistes de n-methyle-d-aspartate utiles dans le traitement de troubles cognitifs |
US9095573B2 (en) * | 2005-08-01 | 2015-08-04 | University Of Central Florida Research Foundation, Inc. | Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF |
RU2327480C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом |
US9006283B2 (en) | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
US8962677B2 (en) | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
US20120225922A1 (en) * | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
US10111860B1 (en) | 2016-01-15 | 2018-10-30 | Aristea Translational Medicine Corporation | Compositions and methods for treating concussion |
US10864192B2 (en) | 2016-01-15 | 2020-12-15 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
US10751340B2 (en) | 2016-06-06 | 2020-08-25 | University Of Central Florida Research Foundation, Inc. | Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions |
CA3083015A1 (fr) * | 2017-05-24 | 2018-11-28 | Qr Pharma, Inc. | Prevention ou traitement d'etats pathologiques dus a une dys-homeostasie des metaux par administration de posiphene a des sujets humains sains ou malades |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1349858B1 (fr) * | 2000-11-02 | 2008-08-27 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Agents permettant la reduction de la proteine precurseur amyloide et le traitement de la demence et procede d'utilisation de tels agents |
-
2003
- 2003-03-12 US US10/386,915 patent/US20040024043A1/en not_active Abandoned
- 2003-03-18 KR KR1020047014635A patent/KR100609381B1/ko not_active IP Right Cessation
- 2003-03-18 BR BR0306855-2A patent/BR0306855A/pt not_active IP Right Cessation
- 2003-03-18 CA CA002476923A patent/CA2476923A1/fr not_active Abandoned
- 2003-03-18 EP EP03723773A patent/EP1490057A4/fr not_active Withdrawn
- 2003-03-18 RU RU2004131214/14A patent/RU2280449C2/ru not_active IP Right Cessation
- 2003-03-18 JP JP2003579808A patent/JP2005526806A/ja active Pending
- 2003-03-18 MX MXPA04009136A patent/MXPA04009136A/es unknown
- 2003-03-18 PL PL03372315A patent/PL372315A1/xx unknown
- 2003-03-18 AU AU2003230683A patent/AU2003230683B2/en not_active Ceased
- 2003-03-18 CN CNA038066815A patent/CN1642541A/zh active Pending
- 2003-03-18 IL IL16399303A patent/IL163993A0/xx unknown
- 2003-03-18 WO PCT/US2003/008407 patent/WO2003082270A1/fr active IP Right Grant
- 2003-03-18 NZ NZ534726A patent/NZ534726A/en unknown
-
2004
- 2004-10-21 HR HR20040992A patent/HRP20040992A2/hr not_active Application Discontinuation
- 2004-10-21 NO NO20044530A patent/NO20044530L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL372315A1 (en) | 2005-07-11 |
RU2280449C2 (ru) | 2006-07-27 |
JP2005526806A (ja) | 2005-09-08 |
KR100609381B1 (ko) | 2006-08-08 |
MXPA04009136A (es) | 2004-12-07 |
AU2003230683B2 (en) | 2006-04-06 |
CA2476923A1 (fr) | 2003-10-09 |
EP1490057A4 (fr) | 2007-07-11 |
NZ534726A (en) | 2006-06-30 |
NO20044530L (no) | 2004-10-21 |
WO2003082270A1 (fr) | 2003-10-09 |
BR0306855A (pt) | 2005-04-05 |
HRP20040992A2 (en) | 2005-02-28 |
CN1642541A (zh) | 2005-07-20 |
AU2003230683A1 (en) | 2003-10-13 |
EP1490057A1 (fr) | 2004-12-29 |
RU2004131214A (ru) | 2005-04-10 |
US20040024043A1 (en) | 2004-02-05 |
KR20040101319A (ko) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1683067A4 (fr) | Procede permettant de depister et de traiter des patients presentant un risque de troubles medicaux | |
AU2003239489A8 (en) | Method of treating dyslipidemic disorders | |
IL164352A0 (en) | Methods for treating tweak-related conditions | |
EP1545700A4 (fr) | Methode de traitement de degats du systeme nerveux central | |
HK1249850A1 (zh) | 治療多發性硬化症的方法 | |
EP1651164A4 (fr) | Composition et methode pour traiter des troubles neurologiques | |
AU2003297761A1 (en) | Methods for treating neurological language disorders | |
EP1419218A4 (fr) | Procede de traitement de naphthe continu | |
AU2003286611A8 (en) | Cytomodulating peptides and methods for treating neurological disorders | |
AU2003272713A8 (en) | A method for treating severe tinnitus | |
EP1476147A4 (fr) | Methodes de traitement de troubles de la vue | |
EP1567198A4 (fr) | Procedes et materiaux destines a traiter des troubles oculaires | |
IL163993A0 (en) | Method for treating cognitive disorders | |
AU2003300042A1 (en) | Method and system for treating depressive and anxiety disorders | |
MXPA03006607A (es) | Metodo combinado para tratar trastornos dependientes de hormonas. | |
EP1695061A4 (fr) | Procede de traitement de troubles neurologiques | |
PL376932A1 (pl) | Sposób traktowania żużla | |
EP1594473A4 (fr) | Composition et procede pour traiter des troubles lies a l'age | |
AU2003299652A8 (en) | Methods for treating diabetes | |
EP1599193A4 (fr) | Methode de traitement de l'hypothyroïdie | |
GB0208897D0 (en) | New method of treatment | |
PL376350A1 (en) | Sludge treatment method | |
AU2003278935A8 (en) | Method and composition for treating neurodegenerative disorders | |
AU2003228813A8 (en) | Methods for treating neuronal disorders | |
AU2003248775A8 (en) | Oligonucleotides for treating proliferative disorders |